首页 > 最新文献

Therapeutic Advances in Chronic Disease最新文献

英文 中文
Recalcitrant nodular scabies showing excellent response to tofacitinib: five case reports. 顽固性结节性疥疮对托法替尼表现出优异的反应:5例报告。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231195632
Yu-Kun Zhao, Jing-Fa Lu, Juan-Hua Liu, Hui-Hui Wu, Lu-Li Song, Chun-Lei Wan, Di-Qing Luo

Scabies is a contagious skin condition caused by Sarcoptes scabiei, and it is always associated with an intense, unbearable, nocturnal deteriorating itch. Its presentations include classic burrows, erythema, pruritic papules, pustules, vesicles, and inflammatory nodules, with diffuse or localized distribution on the finger webs, wrist flexors, elbows, axillae, buttocks, genitalia, and breasts. Nodular scabies is an uncommon clinical variant of scabies. Its management is still challenging for some patients up to date, although topical, intralesional or systemic corticosteroids, topical calcineurin inhibitors, and crotamiton as well as cryotherapy alone or in different combinations are used. We here report five male patients of nodular scabies, aged between 14 and 25 years, who had classical scabies that had been cured by sulfur ointment for at least 4 weeks except for their itching nodules, and their residual pruritic nodules also failed in previous treatments including antihistamines, topical applying and intralesional injection of steroids as well as topical tacrolimus in different combinations before being recruited to this study. The patients were administered tofacitinib 5 mg, twice a day, which led to excellent and rapid improvement for both lesions and symptoms after 1-4 weeks of treatment, respectively, without any associations. During 6 months of follow-up, only one had re-infection of scabies associated with nodules that were cured by sulfur ointment and tofacitinib again. No adverse reaction was observed. The present results suggested that tofacitinib might be a potential agent for nodular scabies with excellent response.

疥疮是由疥疮引起的一种传染性皮肤疾病,它总是与强烈的、难以忍受的、夜间恶化的瘙痒有关。其表现为典型的空洞、红斑、瘙痒丘疹、脓疱、囊泡和炎性结节,弥漫性或局部分布于指蹼、腕屈肌、肘部、腋窝、臀部、生殖器和乳房。结节性疥疮是一种罕见的疥疮临床变种。尽管局部、局部或全身皮质类固醇、局部钙调磷酸酶抑制剂、克罗米顿以及单独或不同组合使用冷冻治疗,但迄今为止,对一些患者的治疗仍然具有挑战性。我们在此报告了5例男性结节性疥疮患者,年龄在14 - 25岁之间,他们患有经典疥疮,除瘙痒结节外,经硫磺软膏治愈至少4周,其残留的瘙痒结节在招募到本研究之前,既往治疗包括抗组胺药,局部应用和局部注射类固醇以及局部使用不同组合的他克莫司均失败。患者给予托法替尼5mg,每天两次,分别在治疗1-4周后,病变和症状均有极好的快速改善,无任何关联。在6个月的随访中,只有1例再次感染疥疮伴结节,并再次使用硫软膏和托法替尼治愈。未见不良反应。本研究结果提示托法替尼可能是治疗结节性疥疮的潜在药物,具有良好的疗效。
{"title":"Recalcitrant nodular scabies showing excellent response to tofacitinib: five case reports.","authors":"Yu-Kun Zhao,&nbsp;Jing-Fa Lu,&nbsp;Juan-Hua Liu,&nbsp;Hui-Hui Wu,&nbsp;Lu-Li Song,&nbsp;Chun-Lei Wan,&nbsp;Di-Qing Luo","doi":"10.1177/20406223231195632","DOIUrl":"https://doi.org/10.1177/20406223231195632","url":null,"abstract":"<p><p>Scabies is a contagious skin condition caused by <i>Sarcoptes scabiei</i>, and it is always associated with an intense, unbearable, nocturnal deteriorating itch. Its presentations include classic burrows, erythema, pruritic papules, pustules, vesicles, and inflammatory nodules, with diffuse or localized distribution on the finger webs, wrist flexors, elbows, axillae, buttocks, genitalia, and breasts. Nodular scabies is an uncommon clinical variant of scabies. Its management is still challenging for some patients up to date, although topical, intralesional or systemic corticosteroids, topical calcineurin inhibitors, and crotamiton as well as cryotherapy alone or in different combinations are used. We here report five male patients of nodular scabies, aged between 14 and 25 years, who had classical scabies that had been cured by sulfur ointment for at least 4 weeks except for their itching nodules, and their residual pruritic nodules also failed in previous treatments including antihistamines, topical applying and intralesional injection of steroids as well as topical tacrolimus in different combinations before being recruited to this study. The patients were administered tofacitinib 5 mg, twice a day, which led to excellent and rapid improvement for both lesions and symptoms after 1-4 weeks of treatment, respectively, without any associations. During 6 months of follow-up, only one had re-infection of scabies associated with nodules that were cured by sulfur ointment and tofacitinib again. No adverse reaction was observed. The present results suggested that tofacitinib might be a potential agent for nodular scabies with excellent response.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231195632"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/1f/10.1177_20406223231195632.PMC10467300.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10128095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Anatomical and functional remodeling of left ventricle in patients with primary aldosteronism and concomitant albuminuria. 原发性醛固酮增多症合并蛋白尿患者左心室的解剖和功能重构。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223221143253
Ting-Wei Kao, Xue-Ming Wu, Che-Wei Liao, Cheng-Hsuan Tsai, Zheng-Wei Chen, Yi-Yao Chang, Bo-Ching Lee, Yu-Wei Chiu, Tai-Shuan Lai, Vin-Cent Wu, Yen-Hung Lin, Chi-Sheng Hung
<p><strong>Background: </strong>Primary aldosteronism (PA) is the leading cause of secondary hypertension globally and is associated with adverse cardiovascular outcomes. However, the cardiac impact of concomitant albuminuria remains unknown.</p><p><strong>Objective: </strong>To compare anatomical and functional remodeling of left ventricle (LV) in PA patients with or without albuminuria.</p><p><strong>Design: </strong>Prospective cohort study.</p><p><strong>Methods: </strong>The cohort was separated into two arms according to the presence or absence of albuminuria (>30 mg/g of morning spot urine). Propensity score matching with age, sex, systolic blood pressure, and diabetes mellitus was performed. Multivariate analysis was conducted with adjustments for age, sex, body mass index, systolic blood pressure, duration of hypertension, smoking, diabetes mellitus, number of antihypertensive agents, and aldosterone level. A local-linear model with bandwidth of 2.07 was used to study correlations.</p><p><strong>Results: </strong>A total of 519 individuals with PA were enrolled in the study, of whom 152 had albuminuria. After matching, the albuminuria group had a higher creatinine level, at baseline. With regard to LV remodeling, albuminuria was independently associated with a significantly higher interventricular septum (1.22 > 1.17 cm, <i>p</i> = 0.030), LV posterior wall thickness (1.16 > 1.10 cm, <i>p</i> = 0.011), LV mass index (125 > 116 g/m<sup>2</sup>, <i>p</i> = 0.023), and medial E/e' ratio (13.61 > 12.30, <i>p</i> = 0.032), and a lower medial early diastolic peak velocity (5.70 < 6.36 cm/s, <i>p</i> = 0.016). Multivariate analysis further revealed that albuminuria was an independent risk factor for elevated LV mass index (<i>p</i> < 0.001) and medial E/e' ratio (<i>p</i> = 0.010). Non-parametric kernel regression also demonstrated that the level of albuminuria was positively correlated with LV mass index. The remodeling of LV mass and diastolic function under the presence of albuminuria distinctly improved after PA treatment.</p><p><strong>Conclusion: </strong>The presence of concomitant albuminuria in patients with PA was associated with pronounced LV hypertrophy and compromised LV diastolic function. These alterations were reversible after treatment for PA.</p><p><strong>Plain language summary: </strong><b>Cardiac Impact of Primary Aldosteronism and Albuminuria</b> Primary aldosteronism and albuminuria has been, respectively, demonstrated to bring about left ventricular remodeling, but the aggregative effect was unknown. We constructed a prospective single-center cohort study in Taiwan. We proposed the presence of concomitant albuminuria was associated with left ventricular hypertrophy and compromised diastolic function. Intriguingly, management of primary aldosteronism was able to restore these alterations. Our study delineated the cardiorenal crosstalk in the setting of secondary hypertension and the role of albuminuria for left ventricula
背景:原发性醛固酮增多症(PA)是全球继发性高血压的主要原因,并与不良心血管结局相关。然而,合并蛋白尿对心脏的影响尚不清楚。目的:比较合并蛋白尿和不合并蛋白尿的PA患者左心室(LV)的解剖和功能重构。设计:前瞻性队列研究。方法:根据有无蛋白尿(晨斑尿>30 mg/g)分为两组。进行与年龄、性别、收缩压和糖尿病相匹配的倾向评分。调整年龄、性别、体重指数、收缩压、高血压病程、吸烟、糖尿病、降压药数量、醛固酮水平等因素进行多因素分析。采用带宽为2.07的局部线性模型研究相关性。结果:共有519名PA患者参加了这项研究,其中152名患有蛋白尿。匹配后,蛋白尿组的肌酐水平高于基线水平。在左室重构方面,尿白蛋白与室间隔(1.22 > 1.17 cm, p = 0.030)、左室后壁厚度(1.16 > 1.10 cm, p = 0.011)、左室质量指数(125 > 116 g/m2, p = 0.023)、内侧E/ E′比(13.61 > 12.30,p = 0.032)和内侧舒张早期峰值流速(5.70 p = 0.016)显著升高独立相关。多因素分析进一步显示,蛋白尿是左室质量指数升高的独立危险因素(p p = 0.010)。非参数核回归也显示蛋白尿水平与左室质量指数呈正相关。经PA治疗后,蛋白尿存在下左室体积重构及舒张功能明显改善。结论:PA患者伴发蛋白尿与明显的左室肥厚和左室舒张功能受损有关。这些改变在治疗PA后是可逆的。原发性醛固酮增多症和蛋白尿对心脏的影响已分别证明原发性醛固酮增多症和蛋白尿可引起左心室重构,但其聚集作用尚不清楚。我们在台湾建立了一项前瞻性单中心队列研究。我们认为伴随性蛋白尿与左心室肥厚和舒张功能受损有关。有趣的是,原发性醛固酮增多症的治疗能够恢复这些改变。我们的研究描述了继发性高血压的心肾串扰和蛋白尿在左心室重构中的作用。未来对潜在病理生理学和治疗学的研究将有助于改善对这类人群的整体护理。
{"title":"Anatomical and functional remodeling of left ventricle in patients with primary aldosteronism and concomitant albuminuria.","authors":"Ting-Wei Kao,&nbsp;Xue-Ming Wu,&nbsp;Che-Wei Liao,&nbsp;Cheng-Hsuan Tsai,&nbsp;Zheng-Wei Chen,&nbsp;Yi-Yao Chang,&nbsp;Bo-Ching Lee,&nbsp;Yu-Wei Chiu,&nbsp;Tai-Shuan Lai,&nbsp;Vin-Cent Wu,&nbsp;Yen-Hung Lin,&nbsp;Chi-Sheng Hung","doi":"10.1177/20406223221143253","DOIUrl":"https://doi.org/10.1177/20406223221143253","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Primary aldosteronism (PA) is the leading cause of secondary hypertension globally and is associated with adverse cardiovascular outcomes. However, the cardiac impact of concomitant albuminuria remains unknown.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To compare anatomical and functional remodeling of left ventricle (LV) in PA patients with or without albuminuria.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Prospective cohort study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The cohort was separated into two arms according to the presence or absence of albuminuria (&gt;30 mg/g of morning spot urine). Propensity score matching with age, sex, systolic blood pressure, and diabetes mellitus was performed. Multivariate analysis was conducted with adjustments for age, sex, body mass index, systolic blood pressure, duration of hypertension, smoking, diabetes mellitus, number of antihypertensive agents, and aldosterone level. A local-linear model with bandwidth of 2.07 was used to study correlations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 519 individuals with PA were enrolled in the study, of whom 152 had albuminuria. After matching, the albuminuria group had a higher creatinine level, at baseline. With regard to LV remodeling, albuminuria was independently associated with a significantly higher interventricular septum (1.22 &gt; 1.17 cm, &lt;i&gt;p&lt;/i&gt; = 0.030), LV posterior wall thickness (1.16 &gt; 1.10 cm, &lt;i&gt;p&lt;/i&gt; = 0.011), LV mass index (125 &gt; 116 g/m&lt;sup&gt;2&lt;/sup&gt;, &lt;i&gt;p&lt;/i&gt; = 0.023), and medial E/e' ratio (13.61 &gt; 12.30, &lt;i&gt;p&lt;/i&gt; = 0.032), and a lower medial early diastolic peak velocity (5.70 &lt; 6.36 cm/s, &lt;i&gt;p&lt;/i&gt; = 0.016). Multivariate analysis further revealed that albuminuria was an independent risk factor for elevated LV mass index (&lt;i&gt;p&lt;/i&gt; &lt; 0.001) and medial E/e' ratio (&lt;i&gt;p&lt;/i&gt; = 0.010). Non-parametric kernel regression also demonstrated that the level of albuminuria was positively correlated with LV mass index. The remodeling of LV mass and diastolic function under the presence of albuminuria distinctly improved after PA treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The presence of concomitant albuminuria in patients with PA was associated with pronounced LV hypertrophy and compromised LV diastolic function. These alterations were reversible after treatment for PA.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Plain language summary: &lt;/strong&gt;&lt;b&gt;Cardiac Impact of Primary Aldosteronism and Albuminuria&lt;/b&gt; Primary aldosteronism and albuminuria has been, respectively, demonstrated to bring about left ventricular remodeling, but the aggregative effect was unknown. We constructed a prospective single-center cohort study in Taiwan. We proposed the presence of concomitant albuminuria was associated with left ventricular hypertrophy and compromised diastolic function. Intriguingly, management of primary aldosteronism was able to restore these alterations. Our study delineated the cardiorenal crosstalk in the setting of secondary hypertension and the role of albuminuria for left ventricula","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223221143253"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/a3/10.1177_20406223221143253.PMC9969461.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10812819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Periprocedural, short-term, and long-term outcomes following transcatheter tricuspid valve repair: a systemic review and meta-analysis. 经导管三尖瓣修复术的围手术期、短期和长期结果:系统回顾和荟萃分析。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231158607
Zexuan Wu, Wengen Zhu, Wulamiding Kaisaier, Miriding Kadier, Runkai Li, Gulpari Tursun, Yugang Dong, Chen Liu, Yili Chen

Background: There has been an increasing use of transcatheter tricuspid valve repair (TTVR) recently. However, the periprocedural, short-term, and long-term outcomes of TTVR remain unclear.

Objectives: To determine the clinical outcomes in patients with significant tricuspid regurgitation undergoing TTVR.

Design: Systematic review and meta-analysis.

Data source and methods: The systematic review and meta-analysis is reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed and EMBASE were searched for clinical trials and observational studies until March 2022. Studies reporting the incidence of clinical outcomes after TTVR were included. The clinical outcomes included periprocedural, short-term (in-hospital or within 30 days), and long-term (>6-month follow-up) outcomes. The primary outcome was all-cause mortality whereas the secondary outcomes included technical success, procedural success, cardiovascular mortality, rehospitalization for heart failure (HHF), major bleeding, and single leaflet device attachment. The incidence of these outcomes across studies was pooled by a random-effects model.

Results: A total of 21 studies with 896 patients were included. A total of 729 (81.4%) patients underwent isolated TTVR while only 167 (18.6%) patients underwent combined mitral and tricuspid valve repair. Over 80% of the patients used coaptation devices while approximately 20% used annuloplasty devices. The median follow-up duration was 365 days. Technical and procedural success was high at 93.9% and 82.1%, respectively. The pooled perioperative, short-term, and long-term all-cause mortality for patients undergoing TTVR was 1.0%, 3.3%, and 14.1%, respectively. The long-term cardiovascular mortality rate was 5.3% while the HHF rate was 21.5%. Major bleeding and single leaflet device attachment were two major complications, accounting for 14.3% and 6.4%, respectively, during long-term follow-up.

Conclusion: TTVR is associated with high procedural success and low procedural and short-term mortality. However, all-cause mortality, cardiovascular mortality, and HHF rates remain high during long-term follow-up.

Registration: PROSPERO (CRD42022310020).

背景:近年来,经导管三尖瓣修复术(TTVR)的应用越来越多。然而,TTVR的围手术期、短期和长期结果尚不清楚。目的:探讨重度三尖瓣反流患者行TTVR的临床效果。设计:系统回顾和荟萃分析。数据来源和方法:系统评价和荟萃分析按照系统评价和荟萃分析首选报告项目(PRISMA)指南进行报告。PubMed和EMBASE检索了临床试验和观察性研究,直到2022年3月。纳入了报道TTVR后临床结果发生率的研究。临床结果包括围手术期、短期(住院或30天内)和长期(>6个月随访)结果。主要结局是全因死亡率,而次要结局包括技术成功、手术成功、心血管死亡率、心力衰竭(HHF)再住院、大出血和单叶装置附着。通过随机效应模型汇总了这些研究结果的发生率。结果:共纳入21项研究,896例患者。共有729例(81.4%)患者接受了单独的TTVR,而只有167例(18.6%)患者接受了二尖瓣和三尖瓣联合修复。超过80%的患者使用适配装置,而大约20%的患者使用环成形术装置。中位随访时间为365天。技术和程序成功率分别为93.9%和82.1%。接受TTVR的患者围手术期、短期和长期全因死亡率分别为1.0%、3.3%和14.1%。长期心血管病死率为5.3%,HHF病死率为21.5%。在长期随访中,大出血和单叶装置附着是两大并发症,分别占14.3%和6.4%。结论:TTVR手术成功率高,手术死亡率和短期死亡率低。然而,在长期随访期间,全因死亡率、心血管死亡率和HHF发生率仍然很高。注册:普洛斯彼罗(CRD42022310020)。
{"title":"Periprocedural, short-term, and long-term outcomes following transcatheter tricuspid valve repair: a systemic review and meta-analysis.","authors":"Zexuan Wu,&nbsp;Wengen Zhu,&nbsp;Wulamiding Kaisaier,&nbsp;Miriding Kadier,&nbsp;Runkai Li,&nbsp;Gulpari Tursun,&nbsp;Yugang Dong,&nbsp;Chen Liu,&nbsp;Yili Chen","doi":"10.1177/20406223231158607","DOIUrl":"https://doi.org/10.1177/20406223231158607","url":null,"abstract":"<p><strong>Background: </strong>There has been an increasing use of transcatheter tricuspid valve repair (TTVR) recently. However, the periprocedural, short-term, and long-term outcomes of TTVR remain unclear.</p><p><strong>Objectives: </strong>To determine the clinical outcomes in patients with significant tricuspid regurgitation undergoing TTVR.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Data source and methods: </strong>The systematic review and meta-analysis is reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed and EMBASE were searched for clinical trials and observational studies until March 2022. Studies reporting the incidence of clinical outcomes after TTVR were included. The clinical outcomes included periprocedural, short-term (in-hospital or within 30 days), and long-term (>6-month follow-up) outcomes. The primary outcome was all-cause mortality whereas the secondary outcomes included technical success, procedural success, cardiovascular mortality, rehospitalization for heart failure (HHF), major bleeding, and single leaflet device attachment. The incidence of these outcomes across studies was pooled by a random-effects model.</p><p><strong>Results: </strong>A total of 21 studies with 896 patients were included. A total of 729 (81.4%) patients underwent isolated TTVR while only 167 (18.6%) patients underwent combined mitral and tricuspid valve repair. Over 80% of the patients used coaptation devices while approximately 20% used annuloplasty devices. The median follow-up duration was 365 days. Technical and procedural success was high at 93.9% and 82.1%, respectively. The pooled perioperative, short-term, and long-term all-cause mortality for patients undergoing TTVR was 1.0%, 3.3%, and 14.1%, respectively. The long-term cardiovascular mortality rate was 5.3% while the HHF rate was 21.5%. Major bleeding and single leaflet device attachment were two major complications, accounting for 14.3% and 6.4%, respectively, during long-term follow-up.</p><p><strong>Conclusion: </strong>TTVR is associated with high procedural success and low procedural and short-term mortality. However, all-cause mortality, cardiovascular mortality, and HHF rates remain high during long-term follow-up.</p><p><strong>Registration: </strong>PROSPERO (CRD42022310020).</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231158607"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/e1/10.1177_20406223231158607.PMC9989399.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9437718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report. 双单抗治疗的儿童斑秃和特应性皮炎患者的头发重新着色和再生:一个病例报告。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231191049
Xin Yan, Munire Tayier, Sin Tong Cheang, Zhongmin Liao, Yi Dong, Yifeng Yang, Yanting Ye, Xingqi Zhang

Alopecia areata (AA) is a chronic inflammatory disease mainly involving Th1 immunoreaction, but Th2 is also involved. A 9-year-old girl presented to our clinic with severe alopecia for 2 months and pruritus-related rashes for 8 years. She was diagnosed with AA and atopic dermatitis (AD), and the Severity of Alopecia Tool (SALT) score was 98. She used a 0.05% halometasone cream (occlusive dressing) topically applied overnight (6 days weekly) for 10 months. After 2 months of treatment, she had regrowth of both black and white hair. However, relapse occurred and she gradually lost all black terminal hair, but white terminal hair remained, with a SALT score of 70. Continuous topical occlusion resulted in white hair regrowth with a SALT score of 20 at the end of month 10. Dupilumab was initially prescribed as a 600-mg subcutaneous injection and maintained at 300 mg every 4 weeks thereafter. Hair repigmentation (10% of whole hair density) started, with black hair shaft appearing at the proximal end in parietal-occipital and occipital areas after three injections at week 12 of dupilumab therapy, with a SALT score of 10. After seven injections at week 28, the percentage of black hair shaft reached up to 90, and she regained her black hair and the pigmented section of hair shaft continued to grow longer at the rate of normal hair growth. Nevertheless, 4 months after termination of dupilumab therapy, the black terminal hair began to fall off, and white vellus hair gradually regrew on the scalp, with a SALT score of 80. Dupilumab induces hair regrowth and repigmentation of white terminal hair without disturbing the anagen phase of hair follicles. Therefore, melanocytes in AA may be a potential target of Th2-related factors. Persistent regrowth of white hair may be used as a signal of Th2 dominance in AA management.

斑秃(Alopecia areata, AA)是一种慢性炎症性疾病,主要涉及Th1免疫反应,但也涉及Th2。一名9岁女童因严重脱发2个月及瘙痒性皮疹8年就诊。她被诊断为AA和特应性皮炎(AD),脱发严重程度(SALT)评分为98分。她使用0.05%卤米松乳膏(闭塞敷料)局部应用过夜(每周6天),持续10个月。治疗2个月后,她的黑发和白发都重新长出来了。然而,复发发生了,她逐渐失去了所有的黑色终末发,但白色终末发仍然存在,SALT评分为70分。在第10个月底,持续的局部阻断导致白发再生,SALT评分为20分。Dupilumab最初为600毫克皮下注射,此后每4周维持300毫克。在dupilumab治疗第12周的三次注射后,头发开始重新着色(占全发密度的10%),在顶枕区和枕区近端出现黑色毛干,SALT评分为10。在第28周注射7次后,黑色毛干的百分比达到90%,她的头发恢复了黑色,毛干的色素部分继续以正常头发生长的速度长得更长。然而,在终止dupilumab治疗4个月后,黑色的终末毛开始脱落,头皮上逐渐长出白色的绒毛毛,SALT评分为80分。杜匹单抗诱导头发再生和白发的重新着色,而不干扰毛囊的生长期。因此,AA中的黑色素细胞可能是th2相关因子的潜在靶点。白发的持续再生可能是在AA管理中Th2优势的信号。
{"title":"Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report.","authors":"Xin Yan,&nbsp;Munire Tayier,&nbsp;Sin Tong Cheang,&nbsp;Zhongmin Liao,&nbsp;Yi Dong,&nbsp;Yifeng Yang,&nbsp;Yanting Ye,&nbsp;Xingqi Zhang","doi":"10.1177/20406223231191049","DOIUrl":"https://doi.org/10.1177/20406223231191049","url":null,"abstract":"<p><p>Alopecia areata (AA) is a chronic inflammatory disease mainly involving Th1 immunoreaction, but Th2 is also involved. A 9-year-old girl presented to our clinic with severe alopecia for 2 months and pruritus-related rashes for 8 years. She was diagnosed with AA and atopic dermatitis (AD), and the Severity of Alopecia Tool (SALT) score was 98. She used a 0.05% halometasone cream (occlusive dressing) topically applied overnight (6 days weekly) for 10 months. After 2 months of treatment, she had regrowth of both black and white hair. However, relapse occurred and she gradually lost all black terminal hair, but white terminal hair remained, with a SALT score of 70. Continuous topical occlusion resulted in white hair regrowth with a SALT score of 20 at the end of month 10. Dupilumab was initially prescribed as a 600-mg subcutaneous injection and maintained at 300 mg every 4 weeks thereafter. Hair repigmentation (10% of whole hair density) started, with black hair shaft appearing at the proximal end in parietal-occipital and occipital areas after three injections at week 12 of dupilumab therapy, with a SALT score of 10. After seven injections at week 28, the percentage of black hair shaft reached up to 90, and she regained her black hair and the pigmented section of hair shaft continued to grow longer at the rate of normal hair growth. Nevertheless, 4 months after termination of dupilumab therapy, the black terminal hair began to fall off, and white vellus hair gradually regrew on the scalp, with a SALT score of 80. Dupilumab induces hair regrowth and repigmentation of white terminal hair without disturbing the anagen phase of hair follicles. Therefore, melanocytes in AA may be a potential target of Th2-related factors. Persistent regrowth of white hair may be used as a signal of Th2 dominance in AA management.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231191049"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/50/10.1177_20406223231191049.PMC10403978.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
State of the art: non-invasive electrical stimulation for the treatment of chronic tinnitus. 技术现状:非侵入性电刺激治疗慢性耳鸣。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223221148061
Shanwen Chen, Maoshan Du, Yang Wang, Yifan Li, Busheng Tong, Jianxin Qiu, Feihu Wu, Yehai Liu

Subjective tinnitus is the perception of sound in the absence of external stimulation. Neuromodulation is a novel method with promising properties for application in tinnitus management. This study sought to review the types of non-invasive electrical stimulation in tinnitus to provide the foothold for further research. PubMed, EMBASE, and Cochrane databases were searched for studies on the modulation of tinnitus by non-invasive electrical stimulation. Among the four forms of non-invasive electrical modulation, transcranial direct current stimulation, transcranial random noise stimulation, and transauricular vagus nerve stimulation yielded promising results, whereas the effect of transcranial alternating current stimulation in the treatment of tinnitus has not been confirmed. Non-invasive electrical stimulation can effectively suppress tinnitus perception in some patients. However, the heterogeneity in parameter settings leads to scattered and poorly replicated findings. Further high-quality studies are needed to identify optimal parameters to develop more acceptable protocols for tinnitus modulation.

主观性耳鸣是在没有外界刺激的情况下对声音的感知。神经调节是一种治疗耳鸣的新方法,具有广阔的应用前景。本研究旨在综述非侵入性电刺激治疗耳鸣的类型,为进一步研究提供依据。我们检索了PubMed、EMBASE和Cochrane数据库中关于非侵入性电刺激调节耳鸣的研究。在非侵入性电调制的四种形式中,经颅直流电刺激、经颅随机噪声刺激和经耳迷走神经刺激取得了很好的效果,而经颅交流电刺激治疗耳鸣的效果尚未得到证实。无创电刺激可有效抑制部分患者的耳鸣感觉。然而,参数设置的异质性导致研究结果分散且重复性差。需要进一步的高质量研究来确定最佳参数,以制定更可接受的耳鸣调制方案。
{"title":"State of the art: non-invasive electrical stimulation for the treatment of chronic tinnitus.","authors":"Shanwen Chen,&nbsp;Maoshan Du,&nbsp;Yang Wang,&nbsp;Yifan Li,&nbsp;Busheng Tong,&nbsp;Jianxin Qiu,&nbsp;Feihu Wu,&nbsp;Yehai Liu","doi":"10.1177/20406223221148061","DOIUrl":"https://doi.org/10.1177/20406223221148061","url":null,"abstract":"<p><p>Subjective tinnitus is the perception of sound in the absence of external stimulation. Neuromodulation is a novel method with promising properties for application in tinnitus management. This study sought to review the types of non-invasive electrical stimulation in tinnitus to provide the foothold for further research. PubMed, EMBASE, and Cochrane databases were searched for studies on the modulation of tinnitus by non-invasive electrical stimulation. Among the four forms of non-invasive electrical modulation, transcranial direct current stimulation, transcranial random noise stimulation, and transauricular vagus nerve stimulation yielded promising results, whereas the effect of transcranial alternating current stimulation in the treatment of tinnitus has not been confirmed. Non-invasive electrical stimulation can effectively suppress tinnitus perception in some patients. However, the heterogeneity in parameter settings leads to scattered and poorly replicated findings. Further high-quality studies are needed to identify optimal parameters to develop more acceptable protocols for tinnitus modulation.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223221148061"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/31/10.1177_20406223221148061.PMC9969452.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10812825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Inheritance and innovation of the diagnosis of peripheral pulmonary lesions. 肺周围性病变诊断的继承与创新。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223221146723
Yang Xia, Qin Li, Changgao Zhong, Kopen Wang, Shiyue Li

As the leading cause of cancer-related deaths worldwide, early detection and diagnosis are crucial to reduce the mortality of lung cancer. To date, the diagnosis of the peripheral pulmonary lesions (PPLs) remains a major unmet clinical need. The urgency of diagnosing PPLs has driven a series of development of the advanced bronchoscopy-guided techniques in the past decades, such as radial probe-endobronchial ultrasonography (RP-EBUS), virtual bronchoscopy navigation (VBN), electromagnetic navigation bronchoscopy (ENB), bronchoscopic transparenchymal nodule access (BTPNA), and robotic-assisted bronchoscopy. However, these techniques also have their own limitations. In this review, we would like to introduce the development of diagnostic techniques for PPLs, with a special focus on biopsy approaches and advanced guided bronchoscopy techniques by discussing their advantages, limitations, and future prospects.

作为全球癌症相关死亡的主要原因,早期发现和诊断对于降低肺癌死亡率至关重要。到目前为止,周围肺病变(ppl)的诊断仍然是一个主要的未满足的临床需求。近几十年来,诊断ppl的迫切性推动了一系列先进的支气管镜引导技术的发展,如桡动脉支气管内超声检查(RP-EBUS)、虚拟支气管镜导航(VBN)、电磁导航支气管镜(ENB)、支气管镜透明支气管结节通路(BTPNA)和机器人辅助支气管镜检查。然而,这些技术也有其自身的局限性。在这篇综述中,我们将介绍ppl诊断技术的发展,特别关注活检方法和先进的引导支气管镜技术,讨论它们的优点、局限性和未来前景。
{"title":"Inheritance and innovation of the diagnosis of peripheral pulmonary lesions.","authors":"Yang Xia,&nbsp;Qin Li,&nbsp;Changgao Zhong,&nbsp;Kopen Wang,&nbsp;Shiyue Li","doi":"10.1177/20406223221146723","DOIUrl":"https://doi.org/10.1177/20406223221146723","url":null,"abstract":"<p><p>As the leading cause of cancer-related deaths worldwide, early detection and diagnosis are crucial to reduce the mortality of lung cancer. To date, the diagnosis of the peripheral pulmonary lesions (PPLs) remains a major unmet clinical need. The urgency of diagnosing PPLs has driven a series of development of the advanced bronchoscopy-guided techniques in the past decades, such as radial probe-endobronchial ultrasonography (RP-EBUS), virtual bronchoscopy navigation (VBN), electromagnetic navigation bronchoscopy (ENB), bronchoscopic transparenchymal nodule access (BTPNA), and robotic-assisted bronchoscopy. However, these techniques also have their own limitations. In this review, we would like to introduce the development of diagnostic techniques for PPLs, with a special focus on biopsy approaches and advanced guided bronchoscopy techniques by discussing their advantages, limitations, and future prospects.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223221146723"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/23/10.1177_20406223221146723.PMC9896091.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9214698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Asia Pacific Pediatric Association (APPA) position statement on the MAFLD definition of fatty liver disease. 亚太儿科协会(APPA)关于脂肪肝疾病MAFLD定义的立场声明。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231164523
Iqbal A Memon, Arit Parkash, Kamran Sadiq, Naglaa M Kamal, Mortada H F El-Shabrawi
{"title":"The Asia Pacific Pediatric Association (APPA) position statement on the MAFLD definition of fatty liver disease.","authors":"Iqbal A Memon,&nbsp;Arit Parkash,&nbsp;Kamran Sadiq,&nbsp;Naglaa M Kamal,&nbsp;Mortada H F El-Shabrawi","doi":"10.1177/20406223231164523","DOIUrl":"https://doi.org/10.1177/20406223231164523","url":null,"abstract":"","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231164523"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/76/10.1177_20406223231164523.PMC10084573.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9358946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can chronic kidney disease staging early predict outcome of large-artery ischemic stroke with impaired renal function? 慢性肾脏疾病早期分期能否预测大动脉缺血性脑卒中合并肾功能受损的预后?
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231153564
Ie-Bin Lian, Ping-Fang Chiu, Yi-Chen Hsieh, Yang-Hao Ou, Chih-Ming Lin
<p><strong>Background: </strong>Ischemic stroke poses a major threat to human beings, and a prompt intravenous thrombolytic management remains the gold standard protocol for stroke sufferers. Although the role of thrombolytic therapy (r-tPA) for ischemic stroke patients and those with underlying impaired renal function has been advocated as effective treating strategy, there is still a lack of investigation as to finding out baseline important variables that are capable of early outcome prediction.</p><p><strong>Objectives: </strong>In this project, we hypothesize that the change of clinical chronic kidney disease (CKD) staging (delta stage = CKD stage after 3-month follow-up - CKD stage at admission) could serve as a crucial predictor of the prognosis of patients.</p><p><strong>Design: </strong>This is a cohort longitudinal retrospective study.</p><p><strong>Sources and methods: </strong>A total of 765 cerebral artery ischemic stroke patients with impaired renal function were recruited and followed up for 1 year. Among them, 116 had received the thrombolytic treatment (r-tPA) after being evaluated at the triage in the emergency department and the rest had not (non-r-tPA). Propensity-matching was applied to compare the mortality between the r-tPA and non-r-tPA groups. Multiple logistic regression (LR) and decision tree (DT) algorithm were used to identify important prediction factors for mortality as well as the improvement in neurological function.</p><p><strong>Results: </strong>The 1-year mortality rates for r-tPA and non-r-tPA groups were 32.8% and 44.4%, respectively. The propensity-matched odds ratio of mortality for the r-tPA group compared with the non-r-tPA group is 0.469, with <i>p</i> = 0.003. Logistic regressions suggest that age, Hct, diabetes mellitus type 2, coronary artery disease, and delta stage are important factors for mortality for the non-r-tPA group, whereas age, diabetes mellitus type 2, chronic heart failure, hospital day, and delta stage are important factors for the r-tPA group. On the usage of antihypertensive drugs, ACEI/ARB was not associated with mortality (<i>p</i> = 0.198), whereas the diuretic was, with odds ratio at 1.619 (<i>p</i> = 0.025), indicating higher mortality after administration. Both LR and DT analyses indicate that delta stage is the most important predictor. For the r-tPA group, patients with delta stage ⩽0 had a 24% mortality, while that for delta stage >0 the mortality is 75%. For non-r-tPA patients, the corresponding mortalities were 30.9 and 66.3, respectively. Delta stage is also useful for predicting patients' improvement of neurological function, assessed by NIHSS, mRS, and Barthel Index. The areas under the curve for the three assessments are 0.83, 0.835, and 0.663, respectively.</p><p><strong>Conclusion: </strong>Large-artery ischemic stroke patients who received thrombolytic treatment had significantly lower mortality, even when presenting underlying impaired renal function. The change of
背景:缺血性脑卒中是人类的重大威胁,及时的静脉溶栓治疗仍然是脑卒中患者的金标准方案。尽管溶栓治疗(r-tPA)在缺血性卒中患者和潜在肾功能受损患者中的作用已被提倡为有效的治疗策略,但仍缺乏能够早期预测预后的基线重要变量的研究。目的:在本项目中,我们假设临床慢性肾脏疾病(CKD)分期的变化(delta期=随访3个月后的CKD分期-入院时的CKD分期)可以作为患者预后的重要预测因素。设计:这是一项队列纵向回顾性研究。来源与方法:共招募765例肾功能受损的脑动脉缺血性脑卒中患者,随访1年。其中116例在急诊科分诊后接受了溶栓治疗(r-tPA),其余未接受(非r-tPA)。采用倾向匹配法比较r-tPA组和非r-tPA组的死亡率。采用多元逻辑回归(LR)和决策树(DT)算法识别死亡率和神经功能改善的重要预测因素。结果:r-tPA组和非r-tPA组的1年死亡率分别为32.8%和44.4%。与非r-tPA组相比,r-tPA组死亡率的倾向匹配优势比为0.469,p = 0.003。Logistic回归分析显示,年龄、Hct、2型糖尿病、冠状动脉疾病和delta期是非r-tPA组患者死亡率的重要因素,而年龄、2型糖尿病、慢性心力衰竭、住院天数和delta期是r-tPA组患者死亡率的重要因素。在降压药的使用方面,ACEI/ARB与死亡率无关(p = 0.198),而利尿剂与死亡率相关,优势比为1.619 (p = 0.025),表明使用降压药后死亡率较高。LR和DT分析均表明delta期是最重要的预测因子。对于r-tPA组,δ期< 0的患者死亡率为24%,而δ期>0的患者死亡率为75%。非r- tpa患者的相应死亡率分别为30.9和66.3。通过NIHSS、mRS和Barthel指数评估,Delta期也可用于预测患者神经功能的改善。三种评价的曲线下面积分别为0.83、0.835和0.663。结论:接受溶栓治疗的大动脉缺血性脑卒中患者死亡率显著降低,即使存在潜在的肾功能受损。在早期预后预测方面,CKD分期(delta期)的变化能够作为r-tPA和非r-tPA患者强有力的临床基线替代指标。长期使用利尿剂可能对这组患者有潜在的危害。此外,delta期与临床长期神经功能评估(NIHSS、mRS和Barthel指数)有良好的相关性,有助于帮助紧急临床决策。
{"title":"Can chronic kidney disease staging early predict outcome of large-artery ischemic stroke with impaired renal function?","authors":"Ie-Bin Lian,&nbsp;Ping-Fang Chiu,&nbsp;Yi-Chen Hsieh,&nbsp;Yang-Hao Ou,&nbsp;Chih-Ming Lin","doi":"10.1177/20406223231153564","DOIUrl":"https://doi.org/10.1177/20406223231153564","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Ischemic stroke poses a major threat to human beings, and a prompt intravenous thrombolytic management remains the gold standard protocol for stroke sufferers. Although the role of thrombolytic therapy (r-tPA) for ischemic stroke patients and those with underlying impaired renal function has been advocated as effective treating strategy, there is still a lack of investigation as to finding out baseline important variables that are capable of early outcome prediction.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;In this project, we hypothesize that the change of clinical chronic kidney disease (CKD) staging (delta stage = CKD stage after 3-month follow-up - CKD stage at admission) could serve as a crucial predictor of the prognosis of patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;This is a cohort longitudinal retrospective study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Sources and methods: &lt;/strong&gt;A total of 765 cerebral artery ischemic stroke patients with impaired renal function were recruited and followed up for 1 year. Among them, 116 had received the thrombolytic treatment (r-tPA) after being evaluated at the triage in the emergency department and the rest had not (non-r-tPA). Propensity-matching was applied to compare the mortality between the r-tPA and non-r-tPA groups. Multiple logistic regression (LR) and decision tree (DT) algorithm were used to identify important prediction factors for mortality as well as the improvement in neurological function.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The 1-year mortality rates for r-tPA and non-r-tPA groups were 32.8% and 44.4%, respectively. The propensity-matched odds ratio of mortality for the r-tPA group compared with the non-r-tPA group is 0.469, with &lt;i&gt;p&lt;/i&gt; = 0.003. Logistic regressions suggest that age, Hct, diabetes mellitus type 2, coronary artery disease, and delta stage are important factors for mortality for the non-r-tPA group, whereas age, diabetes mellitus type 2, chronic heart failure, hospital day, and delta stage are important factors for the r-tPA group. On the usage of antihypertensive drugs, ACEI/ARB was not associated with mortality (&lt;i&gt;p&lt;/i&gt; = 0.198), whereas the diuretic was, with odds ratio at 1.619 (&lt;i&gt;p&lt;/i&gt; = 0.025), indicating higher mortality after administration. Both LR and DT analyses indicate that delta stage is the most important predictor. For the r-tPA group, patients with delta stage ⩽0 had a 24% mortality, while that for delta stage &gt;0 the mortality is 75%. For non-r-tPA patients, the corresponding mortalities were 30.9 and 66.3, respectively. Delta stage is also useful for predicting patients' improvement of neurological function, assessed by NIHSS, mRS, and Barthel Index. The areas under the curve for the three assessments are 0.83, 0.835, and 0.663, respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Large-artery ischemic stroke patients who received thrombolytic treatment had significantly lower mortality, even when presenting underlying impaired renal function. The change of","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231153564"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/98/10.1177_20406223231153564.PMC9940177.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10765179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to air pollution and mortality in patients with chronic obstructive pulmonary disease: a cohort study in South Korea. 空气污染与慢性阻塞性肺疾病患者死亡率的更正:韩国的一项队列研究
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231201066

[This corrects the article DOI: 10.1177/20406223231176175.].

[这更正了文章DOI: 10.1177/20406223231176175.]。
{"title":"Corrigendum to air pollution and mortality in patients with chronic obstructive pulmonary disease: a cohort study in South Korea.","authors":"","doi":"10.1177/20406223231201066","DOIUrl":"https://doi.org/10.1177/20406223231201066","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/20406223231176175.].</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231201066"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/ec/10.1177_20406223231201066.PMC10504827.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10300438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electronic patient-reported outcomes in clinical kidney practice (ePRO Kidney): a process evaluation of educational support for clinicians. 临床肾脏实践中的电子患者报告结果(ePRO肾脏):临床医生教育支持的过程评估。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231173624
Kara Schick-Makaroff, Scott Klarenbach, Jae-Yung Kwon, S Robin Cohen, Joanna Czupryn, Loretta Lee, Robert Pauly, Jennifer M MacRae, Bruce Forde, Richard Sawatzky

Background: Patient-reported outcomes (PROs) are increasingly mandated in kidney care to incorporate patients' perspectives.

Objectives: We assessed whether educational support for clinicians using electronic (e)PROs could enhance person-centered care.

Design: A process evaluation, using a mixed methods longitudinal comparative concurrent design was undertaken of educational support to clinicians on routine use of ePROs. In two urban home dialysis clinics in Alberta, Canada, patients completed ePROs. At the implementation site, clinicians were provided with ePROs and clinician-oriented education via voluntary workshops. At the non-implementation site, neither were provided. Person-centered care was measured using the Patient Assessment of Chronic Illness Care-20 (PACIC-20).

Methods: Longitudinal structural equation models (SEMs) compared change in overall PACIC scores. The interpretive description approach, using thematic analysis of qualitative data, further evaluated processes of implementation.

Results: Data were collected from questionnaires completed by 543 patients, 4 workshops, 15 focus groups, and 37 interviews. There was no overall difference in person-centered care throughout the study, including after delivery of workshops. The longitudinal SEMs revealed substantial individual-level variability in overall PACIC trajectories. However, there was no improvement at the implementation site and no difference between the sites during both the pre- and post-workshop periods. Similar results were obtained for each PACIC domain. Qualitative analysis provided insights into why there was no substantial difference between sites: (1) clinicians wanted to see kidney symptoms, not quality of life, (2) workshops were tailored to clinicians' educational needs, not patients' needs, and (3) variable use of ePRO data by clinicians.

Conclusion: Training clinicians on use of ePROs is complex and likely only part of what is required to enhance person-centered care.

Registration: NCT03149328. https://clinicaltrials.gov/ct2/show/NCT03149328.

背景:在肾脏护理中,患者报告的结果(PROs)越来越多地被要求纳入患者的观点。目的:我们评估对临床医生使用电子(e) pro的教育支持是否可以增强以人为本的护理。设计:采用混合方法纵向比较并行设计,对临床医生常规使用ePROs的教育支持进行过程评估。在加拿大阿尔伯塔省的两个城市家庭透析诊所,患者完成了ePROs。在实施现场,通过自愿讲习班向临床医生提供电子病历和面向临床医生的教育。在未执行地点,两者都没有提供。以人为本的护理采用慢性疾病护理患者评估-20 (PACIC-20)进行测量。方法:采用纵向结构方程模型(sem)比较PACIC总分的变化。解释性描述方法利用定性数据的专题分析,进一步评估了实施过程。结果:通过543例患者的问卷调查、4个研讨会、15个焦点小组和37次访谈收集数据。在整个研究过程中,包括工作坊结束后,以人为中心的护理没有总体差异。纵向sem揭示了整个太平洋轨迹中存在大量的个体水平差异。但是,在讲习班前后期间,执行地点没有任何改善,地点之间也没有差别。在每个PACIC域都得到了类似的结果。定性分析提供了为什么不同地点之间没有实质性差异的见解:(1)临床医生希望看到肾脏症状,而不是生活质量;(2)讲习班是根据临床医生的教育需求而不是患者的需求量身定制的;(3)临床医生对ePRO数据的不同使用。结论:培训临床医生使用ePROs是复杂的,可能只是加强以人为本的护理所需要的一部分。注册:NCT03149328。https://clinicaltrials.gov/ct2/show/NCT03149328。
{"title":"Electronic patient-reported outcomes in clinical kidney practice (ePRO Kidney): a process evaluation of educational support for clinicians.","authors":"Kara Schick-Makaroff,&nbsp;Scott Klarenbach,&nbsp;Jae-Yung Kwon,&nbsp;S Robin Cohen,&nbsp;Joanna Czupryn,&nbsp;Loretta Lee,&nbsp;Robert Pauly,&nbsp;Jennifer M MacRae,&nbsp;Bruce Forde,&nbsp;Richard Sawatzky","doi":"10.1177/20406223231173624","DOIUrl":"https://doi.org/10.1177/20406223231173624","url":null,"abstract":"<p><strong>Background: </strong>Patient-reported outcomes (PROs) are increasingly mandated in kidney care to incorporate patients' perspectives.</p><p><strong>Objectives: </strong>We assessed whether educational support for clinicians using electronic (e)PROs could enhance person-centered care.</p><p><strong>Design: </strong>A process evaluation, using a mixed methods longitudinal comparative concurrent design was undertaken of educational support to clinicians on routine use of ePROs. In two urban home dialysis clinics in Alberta, Canada, patients completed ePROs. At the implementation site, clinicians were provided with ePROs and clinician-oriented education via voluntary workshops. At the non-implementation site, neither were provided. Person-centered care was measured using the Patient Assessment of Chronic Illness Care-20 (PACIC-20).</p><p><strong>Methods: </strong>Longitudinal structural equation models (SEMs) compared change in overall PACIC scores. The interpretive description approach, using thematic analysis of qualitative data, further evaluated processes of implementation.</p><p><strong>Results: </strong>Data were collected from questionnaires completed by 543 patients, 4 workshops, 15 focus groups, and 37 interviews. There was no overall difference in person-centered care throughout the study, including after delivery of workshops. The longitudinal SEMs revealed substantial individual-level variability in overall PACIC trajectories. However, there was no improvement at the implementation site and no difference between the sites during both the pre- and post-workshop periods. Similar results were obtained for each PACIC domain. Qualitative analysis provided insights into why there was no substantial difference between sites: (1) clinicians wanted to see kidney symptoms, not quality of life, (2) workshops were tailored to clinicians' educational needs, not patients' needs, and (3) variable use of ePRO data by clinicians.</p><p><strong>Conclusion: </strong>Training clinicians on use of ePROs is complex and likely only part of what is required to enhance person-centered care.</p><p><strong>Registration: </strong>NCT03149328. https://clinicaltrials.gov/ct2/show/NCT03149328.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231173624"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10301169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Therapeutic Advances in Chronic Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1